VCYT logo

VCYT Veracyte, Inc.

NASDAQ · Medical - Diagnostics & Research · Healthcare

$24.32
+0.31 (+1.30%)

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test …

Market Cap: $1.96Bwww.veracyte.com

Price

No data yet.

Social Signal Score

49
5d
—
30d
50
8 mentions
—
60d
48
16 mentions
—
90d
50
22 mentions
—
news: 20 · marketaux: 1 · rss: 1

Analyst Ratings

22 analysts
Buyconsensus
Strong Buy 0Buy 14Hold 7Sell 1Strong Sell 0
Avg price target$54.14+122.6%
Low $44Median $54High $65
Current Consensus

Revenue

$151.75M+731.21%
$16.43M$61.54M$106.65M$151.75M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$1.66
$1.63–$1.70
7 analysts
FY2026
$1.92+15% YoY
$1.88–$1.96
5 analysts
FY2027
$1.57-18% YoY
$1.51–$1.63
7 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Marc Stapley
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Employees
755
Beta
1.96
Country
US
Piotroski score
6 / 9 (Middling)
Altman Z-score
8.94
www.veracyte.com